Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | XDH | P47989 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15631128 | 0.89 | ERN1 (0.49) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL15631141 | 0.87 | ACLY (0.48) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL1669129 | 0.86 | KDM4E (0.53) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL4443226 | 0.84 | MLYCD (0.53) | LMNAALDH1A1MAPTXDHALOX5 | |
| SCHEMBL10033789 | 0.82 | CA2 (0.53) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL31233493 | 0.81 | KDM4E (0.48) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL13761381 | 0.81 | CA12 (0.54) | LMNATDP1POLBALDH1A1XDH | |
| SCHEMBL15631139 | 0.80 | HDAC6 (0.60) | KDM4EPOLBGAAL3MBTL1MAPT | |
| SCHEMBL16144981 | 0.80 | CA2 (0.55) | KDM4ELMNATDP1POLBGAA | |
| SCHEMBL16144983 | 0.80 | CA2 (0.55) | KDM4ELMNATDP1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544952-B1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIV ANTWERPEN (BE) | 2024-11-06 | — | — | EP | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096088-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | ATG4B, ATG7, ATG4A | KDM4E 962/4885LMNA 3856/4885TDP1 2605/4885 |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | ATG4B, ATG7, BECN1 | KDM4E 1039/4885LMNA 3483/4885TDP1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.